Vonoprazan Tablets 20 Mg – A first-in-class potassium-competitive acid blocker with rapid onset of action.
PROZENCA 20: The Composition of Vonoprazan 20mg is a potassium-competitive acid blocker (PCAB) that inhibits H+, K+-ATPase-mediated gastric acid secretion. PCABs represent an alternative to proton-pump inhibitors for the treatment of acid-related disorders. Unlike proton-pump inhibitors, PCABs are unaffected by CYP2C19 genetic polymorphisms and do not require acid-resistant formulations. Furthermore, vonoprazan is 400 times more potent than the proton-pump inhibitor lansoprazole, due to its ability to accumulate in the gastric corpus mucosa, specifically in the parietal cells.
Recommended by Specialists:
✅Gastroenterologists: It is preferred to treat the disease associated with the treatment of acid-related disorders such as GERD (Gastroesophageal Reflux Disease), erosive esophagitis, and peptic ulcers.
✅General Physicians: In general practice, it is preferable to treat the disease associated with managing acidity, reflux, and gastric protection.
✅Hepatologists: It is preferred to treat the disease associated with managing gastrointestinal complications in liver disease patients
Key benefits of Vonoprazan Tablets 20 Mg – PROZENCA 20:
✅With Resistant patients: Unlike PPIs, it irreversibly binds with the proton pump [H+, K+-ATPase] to manage hyperacidity, making it effective in PPI-resistant patients.
✅Faster actions: Up to 400 times more potent than PPIs, they have a longer and more rapid onset of action compared to PPIS like lansoprazole.
✅Fewer side effects: Less chance of drug interactions and helps to lower the PPI-associated side effects
INDICATIONS:
✅Erosive Esophagitis
✅Peptic ulcers, Stomach ulcers
✅Gastritis
✅GERD








